ArticleACS omega2026
Label-Free Nanostructured Biosensing Platform Based on Depolarized Dynamic Light Scattering for Rapid and Portable Detection of Immunoglobulins in Complex Biological Samples.
Article in ACS omega, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The dynamic behavior of nanoparticles in solution provides valuable insights for biomolecular detection. When nanoparticles exhibit optical anisotropy, their Brownian rotational diffusion can be monitored through depolarized dynamic light scattering (DDLS). For anisotropic particles such as gold nanorods (GNRs), the rotational diffusion coefficient scales inversely with the cube of their hydrodynamic radius, making DDLS highly sensitive to nanoscale binding events. Here, we report a label-free nanostructured biosensing platform based on DDLS that enables rapid, sensitive, and portable detection of immunoglobulins in complex samples. The system integrates bioconjugated GNRs with a custom-built, miniaturized DDLS device to achieve real-time, in loco measurements within approximately ≈10 s, without extensive sample preprocessing. As a proof-of-concept, GNRs functionalized with SARS-CoV-2 nucleocapsid proteins were used to detect specific immunoglobulins in clinical samples. The nanobiosensor exhibited high analytical sensitivity, with a detection limit of 0.16 ng/mL, as determined using spiked samples containing commercial monoclonal anti-N antibodies, highlighting its potential for rapid point-of-care immunoassays in complex biological environments.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.